Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: Diarrhea
Interventions: Invaplex[AR-DETOX], Placebo; Biological · Other
Lead sponsor: PATH; Other
Eligibility: 18 Years to 50 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Influenza
Interventions: VXA-A1.1, Fluzone®, Placebo Tablets, Saline Solution for Placebo IM Injection; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer, EGFR Overexpression, Metastatic Esophageal Carcinoma, HER-2 Positive Esophageal Cancer
Interventions: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51; Biological
Lead sponsor: Pravin T.P Kaumaya; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Indianpolis, Indiana

Conditions: COVID-19 Prevention
Interventions: Ad26.COV2.S; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Gulfport, Mississippi • Norfolk, Nebraska • Albuquerque, New Mexico + 1 more

Conditions: Influenza
Interventions: Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 4
States / cities: Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more

Conditions: Chikungunya Virus Infection
Interventions: VLA1553, Placebo; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 4,128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 44
States / cities: Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 39 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 9,172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 96
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 86 more

Conditions: Influenza
Interventions: Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pneumonia, Pneumococcal
Interventions: V116, PCV15, PPSV23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 717 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more

Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib, Capecitabine, ITI-5000 MTD (Maximum Tolerated Dose); Biological · Drug
Lead sponsor: Immunomic Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • Nashville, Tennessee + 1 more

Conditions: Pneumococcal Disease
Interventions: 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more

Conditions: Influenza
Interventions: CSL's 2009 H1N1 Influenza Vaccine (CSL425), Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 6 Months to 9 Years
Enrollment: 473 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: Chandler, Arizona • Melbourne, Florida • Bardstown, Kentucky + 10 more

Conditions: Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions: MenHibrix (Hib-MenCY-TT), Hib conjugate vaccine (ActHIB); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 22 Months to 60 Months
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 21
States / cities: Little Rock, Arkansas • Fountain Valley, California • Norwich, Connecticut + 15 more

Conditions: Venezuelan Equine Encephalitis Virus Infection
Interventions: Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo; Biological · Other
Lead sponsor: Ichor Medical Systems Incorporated; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant; Biological
Lead sponsor: Madhu Chhanda Choudhary; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: Conway, Arkansas • Little Rock, Arkansas • Sacramento, California + 14 more

Conditions: Influenza
Interventions: Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 3,027 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Sacramento, California • Boca Raton, Florida • Wichita, Kansas + 10 more

Conditions: Influenza Immunization
Interventions: Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 9 Years to 49 Years
Enrollment: 1,308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 16 more

Conditions: SARS-CoV-2 Infection
Interventions: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant); Biological · Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Herpes Zoster, Herpes Zoster Vaccine
Interventions: Herpes Zoster Vaccine GSK1437173A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 7,539 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 25
States / cities: Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more

Conditions: Infections, Meningococcal
Interventions: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 55 Years
Enrollment: 704 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 36
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more

Conditions: Hantaan Virus Disease, Puumala Virus
Interventions: Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM); Combination Product
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Campylobacter Infection
Interventions: ALFQ, CJCV2; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Rotavirus Infections
Interventions: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo; Biological · Other
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

HER-2 B Cell Peptide Vaccine

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Combination HTNV and PUUV DNA Vaccine

Safety and Immunogenicity of CJCV2 With and Without ALFQ

CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults